Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19082949 | 0.83 | KDR (0.34) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL29830292 | 0.82 | SGK1 (0.34) | — | |
| SCHEMBL19082952 | 0.81 | JAK2 (0.32) | JAK2JAK3 | |
| SCHEMBL19082946 | 0.74 | ADORA2A (0.40) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL19082955 | 0.70 | PRKCI (0.33) | JAK2JAK3 | |
| SCHEMBL19082948 | 0.68 | PRKCI (0.36) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL19082960 | 0.68 | NUDT1 (0.36) | JAK2JAK3 | |
| SCHEMBL19082953 | 0.68 | NUDT1 (0.34) | JAK2JAK1JAK3 | |
| SCHEMBL29829258 | 0.64 | PKM (0.33) | — | |
| SCHEMBL17017077 | 0.64 | PKM (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, MT-ND2 | JAK2 4247/4885JAK1 4127/4885TYK2 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.